G. Ferretti

发表

HER2 Protein and Gene Variation between Primary and Metastatic Breast Cancer: Significance and Impact on Patient Care

M. Mottolese, F. Cognetti, A. Fabi, 2011, Clinical Cancer Research.

A small molecule Smac mimic potentiates TRAIL-mediated cell death of ovarian cancer cells.

M. Biffoni, C. Peschle, G. Mariani, 2007, Gynecologic oncology.

Long-term follow-up in breast cancer survivors: a single institution survey.

S. Di Cosimo, A. Alimonti, G. Gravante, 2003, Journal of women's health.

The protective side of progesterone

F. Cognetti, G. Ferretti, A. Felici, 2007, Breast Cancer Research.

Progesterone, progestins, pregnancy and breast cancer risk

G. Ferretti, 2007, Breast Cancer Research and Treatment.

Aromatase inhibitors in post-menopausal metastatic breast carcinoma

M. Pino, M. Milella, F. Cognetti, 2007, Expert opinion on investigational drugs.

New aromatase inhibitors as second‐line endocrine therapy in postmenopausal patients with metastatic breast carcinoma

M. Mottolese, S. Di Cosimo, M. Milella, 2005, Cancer.

Postoperative Hyperprolactinemia Could Predict Longer Disease-Free and Overall Survival in Node-Negative Breast Cancer Patients

S. Barni, V. Torri, G. Curigliano, 2002, Oncology.

Effect of Filgrastim on Serum Lactate Dehydrogenase and Alkaline Phosphatase Values in Early Breast Cancer Patients

S. Di Cosimo, F. Cognetti, A. Fabi, 2004, Cancer investigation.

Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis.

F. Cognetti, A. Fabi, P. Carlini, 2007, Bone.

New approaches to prevent intestinal toxicity of irinotecan-based regimens.

A. Vecchione, A. Alimonti, F. Cognetti, 2004, Cancer treatment reviews.

Impact of five prophylactic filgrastim schedules on hematologic toxicity in early breast cancer patients treated with epirubicin and cyclophosphamide.

S. Di Cosimo, A. Fabi, P. Carlini, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Zoledronic-Acid-Induced Circulating Level Modifications of Angiogenic Factors, Metalloproteinases and Proinflammatory Cytokines in Metastatic Breast Cancer Patients

S. Di Cosimo, A. Alimonti, F. Cognetti, 2005, Oncology.

Clinical Evaluation of the Use of Exemestane as Further Hormonal Therapy after Nonsteroidal Aromatase Inhibitors in Postmenopausal Metastatic Breast Cancer Patients

S. Ricci, S. Di Cosimo, A. Alimonti, 2007, Cancer investigation.

Second- and third-generation aromatase inhibitors as first-line endocrine therapy in postmenopausal metastatic breast cancer patients: a pooled analysis of the randomised trials

S. Cosimo, S. Di Cosimo, M. Milella, 2006, British Journal of Cancer.

HER 2 change between primary and metastatic breast cancer 1 HER 2 PROTEIN AND GENE VARIATION BETWEEN PRIMARY AND METASTATIC BREAST CANCER : SIGNIFICANCE AND IMPACT ON PATIENT CARE

M. Mottolese, F. Cognetti, A. Fabi, 2011 .

Predictive Biomarkers and Personalized Medicine HER 2 Protein and Gene Variation between Primary and Metastatic Breast Cancer : Significance and Impact on Patient Care

M. Mottolese, F. Cognetti, A. Fabi, 2011 .

Oxaliplatin in colon cancer.

S. Barni, M. Mandalà, G. Ferretti, 2004, The New England journal of medicine.

Does granulocyte colony-stimulating factor worsen anemia in early breast cancer patients treated with epirubicin and cyclophosphamide?

A. Ceribelli, M. Mottolese, S. Di Cosimo, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

S. Barni, G. Curigliano, M. Mandalà, 2002, Cancer control : journal of the Moffitt Cancer Center.

Troponin-T and myoglobin plus echocardiographic evaluation for monitoring early cardiotoxicity of weekly epirubicin–paclitaxel in metastatic breast cancer patients

F. Cognetti, S. Tomao, I. Sperduti, 2007, Anti-Cancer Drugs.

Is cardiac troponin T serum level an accurate surrogate for acute doxorubicin-related myocardial injury?

M. Mandalà, M. Milella, F. Cognetti, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Medical Oncology And

M. Mandalà, M. Milella, F. Cognetti, 2022 .

Dramatic Regression of Multiple Brain Metastases from Breast Cancer with Capecitabine: Another Arrow at the Bow?

F. Cognetti, A. Fabi, P. Carlini, 2006, Cancer investigation.

Cisplatin and vinorelbine as second-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) resistant to taxol plus gemcitabine.

A. Goldhirsch, F. D. De Braud, G. Curigliano, 2001, Lung cancer.

PTEN Function at the Interface between Cancer and Tumor Microenvironment: Implications for Response to Immunotherapy

M. Milella, L. Ciuffreda, F. Cognetti, 2020, International journal of molecular sciences.

Detection by denaturant gradient gel electrophoresis of tumor-specific mutations in biopsies and relative bronchoalveolar lavage fluid from resectable non-small cell lung cancer.

U. Pastorino, L. Spaggiari, A. Goldhirsch, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Major bleedings in the comparisons between low-molecular weight heparin versus oral anticoagulant therapy for venous thromboembolism.

M. Mandalà, F. Cognetti, A. Fabi, 2007, Thrombosis Research.

Is recurrent venous thromboembolism after therapy reduced by low-molecular-weight heparin compared with oral anticoagulants?

M. Mandalà, F. Cognetti, A. Fabi, 2006, Chest.

Zoledronic Acid and Angiogenesis

F. Cognetti, A. Fabi, S. Tomao, 2007, Clinical Cancer Research.

Prognostic significance of cytoplasmic p53 overexpression in colorectal cancer. An immunohistochemical analysis.

G. Curigliano, A. Boninsegna, A. Cittadini, 1996, European journal of cancer.

The other side of p53.

F. Cognetti, G. Ferretti, A. Felici, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

Catheter-associated thrombosis: thromboprophylaxis for cancer patients who carry factor V Leiden?

F. Cognetti, A. Fabi, P. Carlini, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Role of BRAF molecular analysis in the management of papillary thyroid carcinoma: analysis of cytological and histological samples

C. Marfisi, E. Chiadini, L. Capelli, 2015, Cytopathology : official journal of the British Society for Clinical Cytology.

Hepatic intra-arterial chemotherapy using a percutaneous catheter in pretreated patients with metastatic colorectal carcinoma.

F. Orsi, F. D. De Braud, G. Curigliano, 2003, Anticancer research.

Taxanes and gemcitabine doublets in the management of HER-2 negative metastatic breast cancer: towards optimization of association and schedule.

F. Cognetti, A. Fabi, P. Carlini, 2008, Anticancer research.

Does adjuvant chemotherapy improve survival in non small cell lung cancer (NSCLC)? A pooled-analysis of 6494 patients in 12 studies, examining survival and magnitude of benefit

R. Gralla, F. Cognetti, D. Giannarelli, 2005 .

Gastric Stump Lymphoma Five Years After Distal Gastrectomy

S. Di Cosimo, G. Ferretti, A. Manicone, 2003, Leukemia & lymphoma.

Acute myeloid leukaemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy

G. Ferretti, P. Papaldo, 2008, Breast Cancer Research and Treatment.

Lineage-specific hematopoietic growth factors.

F. Cognetti, G. Ferretti, P. Papaldo, 2006, The New England journal of medicine.

Does the concurrent use of anthracycline and granulocyte colony-stimulating factor influence the risk of secondary leukaemia in breast cancer women?

S. Di Cosimo, A. Alimonti, F. Cognetti, 2005, Annals of Oncology.

Ado-trastuzumab emtansine (T-DM1) in HER2+ advanced breast cancer patients: does pretreatment with pertuzumab matter?

G. Arpino, D. Generali, K. Cannita, 2017, Future oncology.

Forkhead box P3-positive regulatory T cells in immune surveillance and cancer

G. Ferretti, A. Felici, F. Cognettti, 2007, British Journal of Cancer.

Fibroblast-Induced Paradoxical PI3K Pathway Activation in PTEN-Competent Colorectal Cancer: Implications for Therapeutic PI3K/mTOR Inhibition

S. Shirasawa, M. Milella, L. Ciuffreda, 2022, Frontiers in Oncology.

Delayed emesis induced by moderately emetogenic chemotherapy: do we need to treat all patients? The Italian Group for Antiemetic Research.

A. Favero, C. Boni, M. Tonato, 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

Does CTLA4 influence the suppressive effect of CD25+CD4+ regulatory T cells?

M. Pino, F. Cognetti, G. Ferretti, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Functional and pharmacodynamic evaluation of metronomic cyclophosphamide and docetaxel regimen in castration-resistant prostate cancer.

M. Picardo, A. Baldi, F. Cognetti, 2013, Future oncology.

Transforming Growth Factor-β Signaling and Regulatory T Cells

M. Mandalà, F. Cognetti, G. Ferretti, 2007 .

Does low-molecular-weight heparin influence cancer-related mortality?

M. Mandalà, F. Cognetti, A. Fabi, 2006, Annals of Oncology.

Meta-analysis of the randomized comparisons between low-molecular weight heparin (LMWH) with oral anticoagulants (OA) for the long-term treatment of symptomatic venous thromboembolism (VTE): no difference in cancer-related mortality

F. Cognetti, P. Carlini, D. Giannarelli, 2005 .

Factor v leiden mutation in patients with breast cancer with a central venous catheter: risk of deep vein thrombosis.

F. Orsi, A. Goldhirsch, F. D. De Braud, 2006, Supportive cancer therapy.

Factor V Leiden and G20210A prothrombin mutation and the risk of subclavian vein thrombosis in patients with breast cancer and a central venous catheter.

G. Severi, F. Orsi, A. Goldhirsch, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

T-DM1 and brain metastases: Clinical outcome in HER2-positive metastatic breast cancer.

G. Arpino, K. Cannita, F. Montemurro, 2018, Breast.

Temsirolimus for advanced renal-cell carcinoma.

G. Ferretti, 2007, The New England journal of medicine.

HER2 change between primary and metastatic breast cancer 1 HER2 PROTEIN AND GENE VARIATION BETWEEN PRIMARY AND METASTATIC BREAST CANCER: SIGNIFICANCE AND IMPACT ON PATIENT CARE

M. Mottolese, F. Cognetti, A. Fabi, 2011 .

How to restructure the management of Italian oncological patients during and after COVID-19 pandemic?

F. Cognetti, A. Fabi, G. Ferretti, 2020, European review for medical and pharmacological sciences.

Molecular stool testing for the early detection of colorectal cancer: swan song for p53?

F. Cognetti, A. Fabi, P. Carlini, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

HER2/neu expression and hormonal therapy in early breast cancer: can muddy waters become clear?

M. Mandalà, S. Di Cosimo, A. Alimonti, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

S. Barni, G. Curigliano, M. Mandalà, 2003, Cancer control : journal of the Moffitt Cancer Center.

Incidence of venous thromboembolism in breast cancer patients during chemotherapy with vinorelbine, cisplatin, 5-fluorouracil as continuous infusion (ViFuP regimen): is prophylaxis required?

A. Goldhirsch, F. D. De Braud, G. Curigliano, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

Darbepoetin alfa and history of thromboembolic events.

F. Cognetti, G. Ferretti, A. Felici, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Low-molecular-weight heparin versus oral anticoagulant therapy for the long-term treatment of symptomatic venous thromboembolism: Is there any difference in cancer-related mortality?

M. Mandalà, F. Cognetti, A. Fabi, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Zoledronic acid-associated thrombotic thrombocytopenic purpura.

F. Cognetti, A. Fabi, P. Carlini, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Impressive Long-term Response with Pertuzumab and Trastuzumab in HER2-positive Breast Cancer with Brain Metastasis

F. Cognetti, A. Fabi, A. Vidiri, 2018, In Vivo.

Effect of tamoxifen on GH and IGF-1 serum level in stage I-II breast cancer patients.

G. Curigliano, M. Mandalà, M. Calabró, 2001, Anticancer research.

Second-Degree Type 2 Atrioventricular Block Requiring Permanent Cardiac Pacing in Patients on CDK4/6 Inhibitors: Report of Two Cases

F. Cognetti, M. P. Cicini, C. Nisticò, 2021, Breast Care.

Can the addition of prophylactic filgrastim be considered cost effective in early breast cancer patients treated with epirubicin and cyclophosphamide?

G. Ferretti, P. Papaldo, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Myeloid toxicity in breast cancer patients receiving adjuvant chemotherapy: what is the appropriate use of filgrastim?

F. Cognetti, D. Giannarelli, E. Cortesi, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Iatrogenic gastroduodenal ulcers during hepatic intra-arterial chemotherapy.

F. Orsi, C. Crosta, D. Ravizza, 2003, Hepato-gastroenterology.

Granulocyte colony-stimulating factor-associated complications and increase in leukocyte number.

G. Ferretti, P. Papaldo, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

Is there a benefit by the sequence anastrozole–formestane for postmenopausal metastatic breast cancer women?

S. Cosimo, F. Cognetti, A. Fabi, 2003, The Journal of Steroid Biochemistry and Molecular Biology.

Tumor Microenvironment: Implications in Melanoma Resistance to Targeted Therapy and Immunotherapy

M. Milella, L. Ciuffreda, F. Cognetti, 2020, Cancers.

Morphologic and Molecular Landscape of Pancreatic Cancer Variants as the Basis of New Therapeutic Strategies for Precision Oncology

A. Scarpa, C. Luchini, M. Milella, 2020, International journal of molecular sciences.

Assessment of PTEN and PI3K status in primary breast cancer and corresponding metastases: is it worthwhile?

M. Mottolese, F. Cognetti, A. Fabi, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

From Genetic Alterations to Tumor Microenvironment: The Ariadne’s String in Pancreatic Cancer

A. Scarpa, C. Luchini, V. Corbo, 2020, Cells.

Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

Fernando Maciel Barbosa, Raymond J. McDermott, J. Burke, 2022, The Lancet. Oncology.

AXL Receptor in Breast Cancer: Molecular Involvement and Therapeutic Limitations

M. Milella, L. Ciuffreda, F. Cognetti, 2020, International journal of molecular sciences.

Ras oncogene mutations and survival in patients with lung cancer

F. Cognetti, G. Ferretti, A. Felici, 2006, British Journal of Cancer.

Gilbert's syndrome and fluorouracil toxicity in colorectal cancer patients: which correlation?

S. Barni, M. Mandalà, M. Ghilardi, 2004, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

Colorectal cancer stem cells properties and features: evidence of interleukin-8 involvement

M. Milella, L. Ciuffreda, F. Cognetti, 2019, Cancer drug resistance.

Nail disorders in a woman treated with ixabepilone for metastatic breast cancer.

A. Vecchione, A. Alimonti, F. Cognetti, 2005, Anticancer research.

Recognizing features that are dissimilar in male and female breast cancer: expression of p21Waf1 and p27Kip1 using an immunohistochemical assay.

A. Goldhirsch, G. Viale, G. Curigliano, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

Nanoparticle albumin-bound paclitaxel/liposomal-encapsulated doxorubicin in HER2-negative metastatic breast cancer patients.

G. Arpino, F. Cognetti, A. Fabi, 2020, Future oncology.

High sensitivity of ovarian cancer cells to the synthetic triterpenoid CDDO-Imidazolide.

M. Sporn, M. Biffoni, M. Russo, 2009, Cancer letters.

Erlotinib in pancreatic cancer patients: do we need more information from the NCIC CTG trial?

R. Labianca, M. Mandalà, G. Ferretti, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Do HER-2 positive metastatic breast cancer patients benefit from the use of trastuzumab beyond disease progression? A mono-institutional experience and systematic review of observational studies.

M. Mottolese, S. Di Cosimo, F. Cognetti, 2008, Breast.

HER2 and response to paclitaxel in node-positive breast cancer.

F. Cognetti, Francesco Cognetti, Gianluigi Ferretti, 2008, The New England journal of medicine.

Lumpectomy and tamoxifen alone without additional radiotherapy for women 70 years of age or older with estrogen receptor-positive breast cancer

M. Mandalà, F. Cognetti, A. Fabi, 2005, Breast Cancer Research and Treatment.

HER2/neu role in breast cancer: from a prognostic foe to a predictive friend

F. Cognetti, A. Fabi, G. Ferretti, 2007, Current opinion in obstetrics & gynecology.

What is the real benefit of adjuvant chemotherapy in the Adjuvant Navelbine International Trialist Association trial?

R. Labianca, M. Mandalà, G. Michetti, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Proteasome inhibitors sensitize ovarian cancer cells to TRAIL induced apoptosis

M. Biffoni, C. Peschle, G. Mariani, 2007, Apoptosis.

Docetaxel in Advanced Gastric Cancer Review of the Main Clinical Trials

S. Di Cosimo, A. Alimonti, F. Cognetti, 2003, Acta oncologica.

Pregnancy Levels of Estrogen and Progesterone: The Double-Edged Sword

F. Cognetti, G. Ferretti, A. Felici, 2007, Cancer Epidemiology Biomarkers & Prevention.

Breast and ovarian metastatic localization of signet-ring cell gastric carcinoma.

A. Goldhirsch, G. Curigliano, M. Mandalà, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Venous thromboembolism and cancer: new issues for an old topic.

S. Barni, G. Curigliano, M. Mandalà, 2003, Critical reviews in oncology/hematology.

Subacute motor weakness and left renal mass.

A. Vecchione, S. Di Cosimo, A. Alimonti, 2003, American Journal of Medicine.

Should All Patients With HR-Positive HER2-Negative Metastatic Breast Cancer Receive CDK 4/6 Inhibitor As First-Line Based Therapy? A Network Meta-Analysis of Data from the PALOMA 2, MONALEESA 2, MONALEESA 7, MONARCH 3, FALCON, SWOG and FACT Trials

F. Montemurro, V. Rossi, F. Cognetti, 2019, Cancers.

Response to primary chemotherapy in breast cancer patients with tumors not expressing estrogen and progesterone receptors.

A. Goldhirsch, G. Viale, G. Curigliano, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

Acute toxic gastric mucosal damage induced by Lugol’s iodine spray during chromoendoscopy

P. Carlini, E. Bria, A. Felici, 2005 .

Improved prognosis by trastuzumab of women with HER2-positive breast cancer compared with those with HER2-negative disease.

A. Fabi, G. Ferretti, P. Papaldo, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Immunogenicity and Safety of COVID-19 Vaccine BNT162b2 for Patients with Solid Cancer: A Large Cohort Prospective Study from a Single Institution

F. Cognetti, P. Carlini, D. Giannarelli, 2021, Clinical Cancer Research.

Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy

F. Cognetti, A. Fabi, D. Giannarelli, 2012, BMC Cancer.

Epidermal growth factor receptor gene copy number may predict lapatinib sensitivity in HER2-positive metastatic breast cancer

M. Marino, M. Mottolese, F. Cognetti, 2013, Expert opinion on pharmacotherapy.

A phase II study on metastatic breast cancer patients treated with weekly vinorelbine with or without trastuzumab according to HER2 expression: changing the natural history of HER2-positive disease.

S. Cosimo, M. Pino, M. Mottolese, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Analysis of 4-ABP-DNA adducts and p53 alterations in urinary bladder carcinoma.

G. Curigliano, A. Boninsegna, A. Cittadini, 1999, Anticancer research.

Impact of celecoxib on capecitabine tolerability and activity in pretreated metastatic breast cancer: results of a phase II study with biomarker evaluation

M. Mottolese, M. Milella, F. Cognetti, 2008, Cancer Chemotherapy and Pharmacology.

Incidence of chemotherapy-induced amenorrhea depending on the timing of treatment by menstrual cycle phase in women with early breast cancer.

S. Cosimo, M. Mandalà, S. Di Cosimo, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Addition of either lonidamine or granulocyte colony-stimulating factor does not improve survival in early breast cancer patients treated with high-dose epirubicin and cyclophosphamide.

S. Di Cosimo, A. Fabi, P. Carlini, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Re: Polychemotherapy for early breast cancer: results from the international adjuvant breast cancer chemotherapy randomized Trial.

F. Cognetti, P. Carlini, G. Ferretti, 2007, Journal of the National Cancer Institute.

Re: Ovarian ablation or suppression in premenopausal early breast cancer: results from the International Adjuvant Breast Cancer Ovarian Ablation or Suppression randomized trial.

F. Cognetti, P. Carlini, G. Ferretti, 2007, Journal of the National Cancer Institute.

Epirubicin plus docetaxel in metastatic breast cancer: escalating dose does not improve efficacy. A phase II study.

M. Pino, S. Di Cosimo, F. Cognetti, 2004, Anticancer research.

A phase II study on metastatic breast cancer patients treated with weekly vinorelbine with or without trastuzumab according to HER 2 expression : changing the natural history of HER 2-positive disease

S. Cosimo, M. Pino, M. Mottolese, 2006 .

Pegylated liposomal doxorubicin in combination with gemcitabine: a phase II study in anthracycline-naïve and anthracycline pretreated metastatic breast cancer patients

M. Mottolese, F. Cognetti, A. Fabi, 2006, Cancer Chemotherapy and Pharmacology.

The extension of disease is associated to an increased risk of venous thromboembolism (VTE) in patients with gastrointestinal (GI) carcinoma

S. Barni, A. Rosti, M. Mandalà, 2006, Thrombosis and Haemostasis.

Progress Report on the Palliative Therapy of 100 Patients with Neoplastic Effusions by Intracavitary Low-Dose Interleukin-2

S. Barni, G. Curigliano, M. Mandalà, 2001, Oncology.

Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients: Meta-regression analysis of randomized trials

M. Aapro, F. Puglisi, M. Milella, 2011, Journal of experimental & clinical cancer research : CR.

BRAF status modulates Interelukin-8 expression through a CHOP-dependent mechanism in colorectal cancer

G. Blandino, M. Diodoro, S. Shirasawa, 2020, Communications Biology.

BRAF status modulates Interelukin-8 expression through a CHOP-dependent mechanism in colorectal cancer

G. Blandino, M. Diodoro, S. Shirasawa, 2020, Communications biology.

Lonidamine: efficacy and safety in clinical trials for the treatment of solid tumors.

Paolo Carlini, S. Di Cosimo, F. Cognetti, 2003, Drugs of today.

Re: Treatment of human epidermal growth factor receptor 2 overexpressing breast cancer xenografts with multiagent human epidermal growth factor receptor targeted therapy.

F. Cognetti, G. Ferretti, A. Felici, 2007, Journal of the National Cancer Institute.

Can colorectal cancer patients with thymidylate synthase-overexpressing liver metastases have an overall survival advantage with hepatic arterial infusion alone?

A. Vecchione, S. Di Cosimo, A. Alimonti, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Self-monitoring versus standard monitoring of oral anticoagulation.

M. Mandalà, F. Cognetti, P. Carlini, 2007, Thrombosis research.

Old age: biologic versus chronologic.

M. Milella, F. Cognetti, C. Nuzzo, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Is thymidylate synthase a reliable predictor for response and survival during hepatic arterial infusion for hepatic metastases from colorectal cancer?

A. Alimonti, F. Cognetti, G. Ferretti, 2006, British Journal of Cancer.

Weekly Docetaxel in Pretreated Metastatic Breast Cancer Patients: A Phase I-II Study

S. Barni, L. Frontini, M. Milella, 2005, Oncology.

A man with a deltoid swelling and paraneoplastic erythrocytosis: case report.

A. Vecchione, S. Di Cosimo, A. Alimonti, 2003, Anticancer research.

Detection of oncogene mutation from neoplastic colonic cells exfoliated in feces

G. Curigliano, A. Cittadini, C. Ratto, 1996, Diseases of the colon and rectum.

Prospective study on nanoparticle albumin-bound paclitaxel in advanced breast cancer: clinical results and biological observations in taxane-pretreated patients

M. Caterino, M. Mottolese, F. Cognetti, 2015, Drug design, development and therapy.

Transforming growth factor-beta signaling and regulatory T cells.

M. Mandalà, F. Cognetti, G. Ferretti, 2007, Journal of Clinical Oncology.

Prostate cancer: the role of hormonal therapy.

F. Cognetti, P. Carlini, E. Bria, 2005, Journal of experimental & clinical cancer research : CR.

Prognostic value of [18F]-FDG PET/CT in patients with meta-static breast cancer treated with cyclin-dependent inhibitors

F. Cappuzzo, A. Annovazzi, R. Sciuto, 2023, Frontiers in oncology.

A man who bled from his nose: A rare case of fatal myelophthisis as solitary manifestation of solid tumour

G. Curigliano, S. Cosimo, M. Mandalà, 2003 .

Bone scan had no role in the staging of 765 consecutive operable T(1-2)N(0-1) breast cancer patients without skeletal symptoms.

A. Goldhirsch, G. Curigliano, M. Colleoni, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Chemotherapy-induced amenorrhea in early breast cancer.

F. Cognetti, A. Fabi, P. Carlini, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Is anthracycline-based chemotherapy alone adequate for young women with estrogen receptor-positive breast cancer?

S. Di Cosimo, F. Cognetti, A. Fabi, 2006, Breast.

Activity of trastuzumab (t) beyond disease progression in HER2 over-expressing metastatic breast cancer (MBC)

S. Cosimo, M. Mottolese, F. Cognetti, 2007 .

Breast Cancer Metastatic to the Choroid in a Male Patient Case Report

S. Di Cosimo, N. Silvestris, G. Ferretti, 2003, Tumori.

Liver toxicity after treatment with gefitinib and anastrozole: drug-drug interactions through cytochrome p450?

M. Milella, F. Cognetti, A. Fabi, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

p53 and BLC2 Immunohistochemical Expression Across Molecular Subtypes in 1099 Early Breast Cancer Patients With Long-Term Follow-up: An Observational Study.

E. Pescarmona, M. Mottolese, F. Cognetti, 2020, Clinical breast cancer.

of chemotherapy-induced alopecia with paclitaxel in a case of hypothyroidism:

S. Cosimo, F. Cognetti, A. Fabi, 2003 .